Cwm LLC Boosts Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Cwm LLC lifted its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 713.6% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 6,517 shares of the company’s stock after acquiring an additional 5,716 shares during the quarter. Cwm LLC’s holdings in Pacira BioSciences were worth $98,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in PCRX. Pacer Advisors Inc. raised its holdings in Pacira BioSciences by 37.5% in the second quarter. Pacer Advisors Inc. now owns 2,162,787 shares of the company’s stock worth $61,877,000 after purchasing an additional 590,082 shares in the last quarter. Archon Capital Management LLC purchased a new position in Pacira BioSciences in the 1st quarter worth approximately $15,677,000. Fort Washington Investment Advisors Inc. OH bought a new stake in shares of Pacira BioSciences in the 2nd quarter worth $13,240,000. Doma Perpetual Capital Management LLC increased its holdings in Pacira BioSciences by 71.8% in the 2nd quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company’s stock worth $28,632,000 after buying an additional 418,321 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Pacira BioSciences by 12.2% in the second quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock worth $52,300,000 after acquiring an additional 198,936 shares during the period. 99.73% of the stock is owned by institutional investors.

Analysts Set New Price Targets

PCRX has been the subject of several research reports. Jefferies Financial Group upped their price target on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Barclays downgraded Pacira BioSciences from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $38.00 to $25.00 in a research note on Wednesday, July 3rd. Truist Financial cut shares of Pacira BioSciences from a “buy” rating to a “sell” rating and reduced their price objective for the stock from $30.00 to $8.00 in a research note on Tuesday, August 13th. StockNews.com downgraded Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 12th. Finally, HC Wainwright decreased their price target on shares of Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $24.20.

Insider Activity at Pacira BioSciences

In other Pacira BioSciences news, CEO Frank D. Lee bought 8,264 shares of the company’s stock in a transaction on Monday, August 12th. The stock was acquired at an average price of $12.10 per share, for a total transaction of $99,994.40. Following the completion of the transaction, the chief executive officer now directly owns 107,784 shares of the company’s stock, valued at approximately $1,304,186.40. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have bought 11,176 shares of company stock worth $136,240. Insiders own 6.40% of the company’s stock.

Pacira BioSciences Stock Performance

NASDAQ PCRX opened at $16.83 on Friday. The business’s 50 day moving average price is $15.10 and its 200-day moving average price is $21.69. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $35.95. The company has a market cap of $776.37 million, a P/E ratio of 12.85 and a beta of 0.84. The company has a debt-to-equity ratio of 0.67, a quick ratio of 5.70 and a current ratio of 6.82.

Pacira BioSciences (NASDAQ:PCRX) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.53 by $0.11. The business had revenue of $178.02 million for the quarter, compared to analysts’ expectations of $173.31 million. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. Sell-side analysts predict that Pacira BioSciences, Inc. will post 2.24 earnings per share for the current year.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.